CIK 0001604821 · Large accelerated filer
Natera, Inc.
Sign in to watch- Ticker
- NTRA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 010894487
- Phone
- 650-249-9090
- Business address
- 13011 MCCALLEN PASS, BUILDING A SUITE 100, AUSTIN, TX, 78753
- Former names
- Natera, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $104,832,418
- in 28 filings, $104.8M under 10b5-1 plans
Net −$104,832,418. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Rabinowitz Matthew −$72.3M EXECUTIVE CHAIRMAN sold 9% of stake
- Sheena Jonathan −$13.8M Director sold 83% of stake
- Moshkevich Solomon −$9.5M PRESIDENT, CLINICALDIAGNOSTICS sold 21% of stake
- Chapman Steven Leonard −$5.0M CEO AND PRESIDENT sold 12% of stake
- Brophy Michael Burkes −$2.5M CHIEF FINANCIAL OFFICER sold 11% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-04-28 | Chapman Steven Leonard CEO AND PRESIDENT | Sale 10b5-1 | −6,203 | $152.18 | $944K | 192,162 |
| 2025-04-28 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −2,018 | $152.18 | $307K | 73,539 |
| 2025-04-25 | ROSENMAN HERM Director | Grant or award | +164 | 66,062 | ||
| 2025-04-25 | HEALY JAMES Director | Grant or award | +142 | 46,260 | ||
| 2025-04-25 | BOTHA ROELOF Director | Grant or award | +185 | 4,103 | ||
| 2025-04-25 | Baynes Roy D. Director | Grant or award | +116 | 16,015 | ||
| 2025-04-24 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −561 | $152.45 | $86K | 75,751 |
| 2025-04-24 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −194 | $152.46 | $30K | 75,557 |
| 2025-04-23 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −495 | $150.74 | $75K | 76,312 |
| 2025-04-22 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −308 | $144.30 | $44K | 76,160 |
| 2025-04-22 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −603 | $145.35 | $88K | 75,557 |
| 2025-04-22 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +1,250 | 76,807 | ||
| 2025-04-22 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Option exercise · Restricted Stock Unit 10b5-1 | −1,250 | 2,500 | ||
| 2025-04-21 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −602 | $145.54 | $88K | 76,476 |
| 2025-04-21 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −8 | $146.16 | $1K | 76,468 |
| 2025-04-21 | Chapman Steven Leonard CEO AND PRESIDENT | Sale 10b5-1 | −1,643 | $145.54 | $239K | 198,386 |
| 2025-04-21 | Chapman Steven Leonard CEO AND PRESIDENT | Sale 10b5-1 | −21 | $146.07 | $3K | 198,365 |
| 2025-04-21 | Fesko John PRESIDENT, CHIEF BUS. OFFICER | Sale 10b5-1 | −339 | $145.54 | $49K | 156,950 |
| 2025-04-21 | Fesko John PRESIDENT, CHIEF BUS. OFFICER | Sale 10b5-1 | −4 | $146.10 | $584 | 156,946 |
| 2025-04-21 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −292 | $145.54 | $42K | 141,490 |
Page 48 of 55 · 1,093 trades